Biolegend, 480035, MojoSort™ Mouse CD8 T Cell Isolation Kit
200tests
Catalog Number: 480035
Send an RFQ.
Category
| Verified Reactivity | Mouse |
|---|---|
| Formulation | Cocktail: Phosphate-buffered solution containing 0.09% sodium azide, pH 7.2.Streptavidin Nanobeads: Aqueous solution containing BSA and 0.05% sodium azide. |
| Preparation | The antibodies were purified by affinity chromatography, and conjugated with biotin under optimal conditions.Streptavidin Nanobeads: Streptavidin-coated magnetic beads. |
| Storage & Handling | Antibody cocktail and Streptavidin Nanobeads should be stored undiluted between 2°C and 8°C. |
| Application | Cell Separation (MojoSort™) - Quality tested |
| Recommended Usage | 10 µl of antibody cocktail for 1x107 cells in 100 µl of buffer. 10 µl Streptavidin Nanobeads for 1x107 cells in 100 µl of buffer. |
| Application Notes | This kit is designed for the isolation of untouched CD8+ T cells from lymphoid tissues. Each lot has been individually optimized. Do not mix and match components from different lots or different kits. Antibody or cocktail dilution to use in column: 10X Nanobead dilution to use in columns: 8X |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Product Citations |
|---|
| Ma S, et al. 2018. Cell. 173:443. PubMed Li L, et al. 2022. Cancer Immunol Res. 10:1475. PubMed Yang Y, et al. 2023. Front Immunol. 14:1033497. PubMed Gao R, et al. 2022. FEBS J. 289:4518. PubMed Li YJ, et al. 2022. Cell Rep. 39:110870. PubMed An HW, et al. 2022. Cell Rep. 41:111878. PubMed Wang R, et al. 2023. iScience. 26:105954. PubMed Tan L, et al. 2022. Aging Dis. 13:1562. PubMed Dai K, et al. 2017. Front Immunol. 0.555555556. PubMed Pan YC, et al. 2021. Mol Ther Oncolytics. 20:175. PubMed Lv M, et al. 2020. Cell Res. 30:966. PubMed Yang P, et al. 2022. Nat Commun. 13:5782. PubMed Cheng Y, et al. 2020. PLoS Pathog. 16:e1008569. PubMed Bai C, et al. 2020. Mol Ther Oncolytics. 17:9. PubMed Tang X, et al. 2022. Cell Rep. 41:111673. PubMed Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed Nabe S, et al. 2018. Cancer Sci. 109:3737. PubMed Duan H, et al. 2021. J Clin Invest. 131:. PubMed Li ZL, et al. 2020. Nat Commun. 3.101388889. PubMed Itoh G, et al. 2021. Mol Oncol. Online ahead of print.. PubMed Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed Ma C, et al. 2017. J Immunol. 198(2):749-756. PubMed Yin X, et al. 2020. Cell Rep. 33:108278. PubMed Aguilar–Valenzuela R, et al. 2018. J Virol. 92:e00014. PubMed Mosaheb MM, et al. 2020. Nat Commun. 11:524. PubMed Yan J, et al. 2019. Nat Commun. 0.727777778. PubMed Qin J, et al. 2020. Cancer Immunol Res. 8:1426. PubMed Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed Xie L, et al. 2020. Infect Immun. :88. PubMed Dai X, et al. 2020. Theranostics. 6.897222222. PubMed Lucas ED, et al. 2020. Cell Reports. 33(2):108258. PubMed Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed |
| Biology Area | Immunology |
|---|
| Molecular Family | CD Molecules |
|---|
| Gene ID | NA |
|---|
| UniProt | View information about CD8 on UniProt.org |
|---|
| Regulatory Status | RUO |
|---|